Chordia Therapeutics (TYO:190A) has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.
This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's (AMED) Research Project for Innovative Cancer Therapy Application.
While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。